Effects of chronic sumatriptan and zolmitriptan treatment on 5-HT 1 receptor expression and function in rats

Cephalalgia

Volumn 24, Issue 5, 2004, Pages 398-407

  Reuter, U ^a,b   Salomone, S ^a,c   Ickenstein, G W ^a,d   Waeber, C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HUMBOLDT UNIVERSITY   (Germany)

^c UNIVERSITY OF CATANIA   (Italy)

^d UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

5 HT1 receptor; Drug overuse; Protein extravasation; Triptan; Vasoconstriction

Indexed keywords

5 NONYLOXYTRYPTAMINE; GUANOSINE 5' O (3 THIO)TRIPHOSPHATE; MESSENGER RNA; PHOSPHORUS DERIVATIVE; SEROTONIN 1 RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SUMATRIPTAN; TRYPTAMINE DERIVATIVE; UNCLASSIFIED DRUG; ZOLMITRIPTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASILAR ARTERY; CONTROLLED STUDY; CORONARY ARTERY; DRUG DETERMINATION; DRUG EFFECT; DRUG MECHANISM; DURA MATER; LONG TERM CARE; MIGRAINE; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; RECEPTOR INTRINSIC ACTIVITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUBSTANTIA NIGRA; TISSUE DISTRIBUTION; TRIGEMINUS GANGLION; VASOCONSTRICTION;

ANIMALS; AUTORADIOGRAPHY; BASILAR ARTERY; CORONARY VESSELS; DURA MATER; MALE; ORGAN CULTURE TECHNIQUES; OXAZOLIDINONES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SEROTONIN, 5-HT1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEROTONIN AGONISTS; SUMATRIPTAN; TIME FACTORS; TRIGEMINAL GANGLION; TRYPTAMINES; VASOCONSTRICTION;

EID: 2442604547     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-2982.2004.00683.x     Document Type: Article

References (33)

1. Silberstein SD, Liu D. Drug overuse and rebound headache. Curr Pain Headache Rep 2002; 6:240-7.
2. Katsarava Z, Diener HC, Limmroth V. Medication overuse headache: a focus on analgesics, ergot alkaloids and triptans. Drug Saf 2001; 24:921-7.
3. Evers S, Gralow I, Bauer B, Suhr B, Buchheister A, Husstedt IW, Ringelstein EB. Sumatriptan and ergotamine over-use and drug-induced headache: a clinicoepidemiologic study. Clin Neuropharmacol 1999; 22:201-6.
4. Borgland SL. Acute opioid receptor desensitization and tolerance: is there a link? Clin Exp Pharmacol Physiol 2001; 28:147-54.
5. Gaist D. Use and overuse of sumatriptan. Pharmacoepidemiological studies based on prescription register and interview data. Cephalalgia 1999; 19:735-61.
6. Centonze V, Bassi A, Causarano V, Dalfino L, Cassiano MA, Centonze A et al. Sumatriptan overuse in episodic duster headache: lack of adverse events, rebound syndromes, drug dependence and tachyphylaxis. Funct Neurol 2000; 15:167-70.
7. Evers S, Suhr B, Bauer B, Grotemeyer KH, Husstedt IW. A retrospective long-term analysis of the epidemiology and features of drug-induced headache. J Neurol 1999; 246:802-9.
8. Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 2000; 60:1259-87.
9. Silberstein SD. The pharmacology of ergotamine and dihydroergotamine. Headache 1997; 37 (Suppl. 1):S15-25.
10. May A, Goadsby PJ. The trigeminovascular system in humans: pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation. J Cereb Blood Flow Metab 1999; 19:115-27.
11. 1B receptors. Mol Pharmacol 1996; 49:761-5.
12. 1B/1D receptor partial agonist, 311C90 (zolmitriptan). Br J Pharmacol 1997; 121:157-64.
13. 1B/1D) agonists in a model of trigeminovascular nociception in cat. Exp Neurol 1998; 150:45-51.
14. Buzzi MG, Moskowitz MA. The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br J Pharmacol 1990; 99:202-6.
15. Mulvany MJ, Halpern W. Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ Res 1977; 41:19-26.
16. Bobker DH, Williams JT. Serotonin augments the cationic current Ih in central neurons. Neuron 1989; 2:1535-40.
17. 35S]guanosine-5′-O-(3-thio) triphosphate binding to rodent brain sections as visualized by in vitro autoradiography. Mol Pharmacol 1997; 52:623-31.
18. 2C, receptor. Psychopharmacology (Berl) 1999; 144:248-54.
19. 1A receptor agonist flesinoxan on rat 5-HT neurotransmission. Eur Neuropsychopharmacol 1999; 9:427-40.
20. 35S]-GTPγS binding as measured by quantitative autoradiography following chronic agonist administration. Br J Pharmacol 2001; 132:605-11.
21. Nishimura Y. Characterization of 5-hydroxytryptamine receptors mediating contractions in basilar arteries from stroke-prone spontaneously hypertensive rats. Br J Pharmacol 1996; 117:1325-33.
22. Hansen-Schwartz J, Svensson CL, Xu CB, Edvinsson L. Protein kinase mediated upregulation of endothelin A, endothelin B and 5-hydroxytryptamine 1B/1D receptors during organ culture in rat basilar artery. Br J Pharmacol 2002; 137:118-26.
23. Lai FM, Tanikella T, Cervoni P. Characterization of serotonin receptors in isolated rat intramyocardial coronary artery. J Pharmacol Exp Ther 1991; 256:164-8.
24. 1D receptors. Naunyn Schmiedebergs Arch Pharmacol 1989; 340:135-8.
25. 1A receptors: intrinsic activity and modulation by G-protein activation state. Naunyn Schmiedebergs Arch Pharmacol 1998; 357:490-9.
26. MaassenVanDenBrink A, Reekers M, Bax WA, Ferrari MD, Saxena PR. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 1998; 98:25-30.
27. 1B/1D agonist for migraine. Cephalalgia 1997; 17 (Suppl. 18):4-14.
28. 1B/1D/1F receptors and glutamate in trigeminal ganglia in rats. Neuroreport 2001; 12:1589-91.
29. Chen JJ, Vasko MR, Wu X, Staeva TP, Baez M, Zgombick JM, Nelson DL. Multiple subtypes of serotonin receptors are expressed in rat sensory neurons in culture. J Pharmacol Exp Ther 1998; 287:1119-27.
30. Hoskin KL, Kaube H, Goadsby PJ. Sumatriptan can inhibit trigeminal afferents by an exclusively neural mechanism. Brain 1996; 119:1419-28.
31. Kaube H, Hoskin KL, Goadsby PJ. Inhibition by sumatriptan of central trigeminal neurones only after blood-brain barrier disruption. Br J Pharmacol 1993; 109:788-92.
32. 1B/1D receptor partial agonist for the acute treatment of migraine. Eur J Pharmacol 1998; 361:191-7.
33. 1B receptor binding sites in the central nervous system. Neuropsychopharmacology 1994; 10:259-64.